Core Viewpoint - The recent passing of the revised Biological Safety Act as part of the U.S. National Defense Authorization Act (NDAA) for fiscal year 2026 is expected to positively impact the innovative drug sector, leading to a recovery in stock prices and a return to long-term growth logic for the industry [1][2]. Group 1: Market Reaction - A-shares and Hong Kong stocks in the innovative drug sector saw significant gains, with companies like Huaren Health and Saily Medical reaching their daily limit up [1]. - The Hong Kong Stock Connect Innovative Drug ETF (520880) has experienced net inflows for seven consecutive days, with its fund size reaching a record high of 4.172 billion shares [1]. Group 2: Legislative Impact - The revised Biological Safety Act was passed with a vote of 77 in favor and 20 against, and it will be managed by the Office of Management and Budget (OMB) to create a list of restricted companies within a year [2]. - Analysts believe that the passage of the act marks a significant milestone for the industry, allowing for a return to a long-term growth perspective [2]. Group 3: Industry Outlook - The CXO sector has shown improved valuation attractiveness following adjustments in Q4 2025, with expectations for continued upward trends in 2026 [3]. - External factors affecting the CXO industry, such as the U.S. Biological Safety Act and drug tariffs, are showing signs of marginal improvement, leading to a more favorable sentiment [4]. - The overall demand for CXO services is on the rise, with both order volumes and financing showing positive trends [4]. Group 4: Strategic Partnerships - Recent collaborations, such as the agreement between Senrida Medical and Boston Scientific, indicate increased interest from leading global pharmaceutical companies in Chinese innovative medical devices [5]. - The medical device sector is positioned to benefit from advancements in medical information technology and AI applications, enhancing productivity [5].